CooperCompanies stock trades steadily as contact lens growth supports earnings

CooperCompanies (ISIN US21664P1039) stock represents one of the established names in specialty medical devices, particularly in soft contact lenses and women’s health. In its most recently reported fiscal year, CooperCompanies disclosed that consolidated revenue rose compared with the prior year, underpinned by expansion in both its CooperVision contact lens division and its CooperSurgical women’s health portfolio, according to the company’s published annual results as of late 2025. Investors following CooperCompanies stock are therefore looking at a business whose top line is still driven primarily by recurring demand from eye care professionals and clinics worldwide.

Revenue and earnings trends show continued growth

According to the latest available annual report on CooperCompanies’ investor relations site as of 2025, group revenue reached approximately $3.1 billion for the fiscal year ended 31 October 2025, compared with about $2.9 billion in fiscal 2024. This implies year over year growth of roughly seven percent in reported terms, indicating that demand for its core products, especially premium contact lenses, remains resilient. The same filing shows that, alongside revenue expansion, CooperCompanies generated operating income in the several hundred million dollar range, with operating margin in the mid teens as a percentage of sales in fiscal 2025, broadly similar to or slightly higher than the margin recorded in fiscal 2024.

Within this overall revenue figure, CooperVision accounted for the majority of sales. The division, which concentrates on soft contact lenses including daily disposables, spherical lenses, toric lenses for astigmatism, and multifocal products, delivered revenue that climbed from roughly $2.0 billion in fiscal 2024 to around $2.1 billion in fiscal 2025. This approximately five percent year over year increase stems from a mix that continues to tilt toward higher value silicone hydrogel lenses and daily disposable formats, which generally carry higher average selling prices and contribute positively to gross margin. CooperSurgical, focused on women’s health, fertility, and prenatal diagnostics, contributed close to $1.0 billion in revenue, expanding at a mid single digit pace compared with the prior year period.

Net income attributable to CooperCompanies shareholders for fiscal 2025, as reported in the same annual document, stood in the low to mid hundreds of millions of dollars, slightly above the level in fiscal 2024. On a per share basis, diluted earnings per share were in the high single digit to low double digit dollar range, reflecting both the higher operating earnings and the impact of ongoing share repurchases that reduce the average diluted share count. For investors analyzing CooperCompanies stock, these figures suggest that earnings growth has broadly tracked the expansion in revenue and that profitability is being preserved even as the company continues to invest in product development and market expansion.

Margin profile and cash flow support investment capacity

CooperCompanies’ reported gross margin in fiscal 2025 remained in the mid sixties percent area, consistent with the previous year, according to the company’s financial disclosures. This margin level reflects the combined effect of the higher value mix in CooperVision, the manufacturing efficiency gains from scale, and the relatively attractive economics of certain CooperSurgical devices and fertility products. Operating margin, after research and development, selling, general and administrative expenses, and amortization of intangible assets, stayed in the mid teens percentage range, which is typical for a diversified medical device maker with a strong recurring revenue base.

Cash flow figures in the latest annual report show that CooperCompanies generated operating cash flow in the several hundred million dollar range in fiscal 2025, slightly above the prior fiscal year. Capital expenditures, mainly associated with capacity enhancements in contact lens manufacturing plants and investments in CooperSurgical facilities, consumed a fraction of this operating cash flow, leaving the company with substantial free cash flow that can be allocated to debt reduction, bolt on acquisitions, or share repurchases. The company’s balance sheet, as presented in the same filing, shows total debt in the low billions of dollars, balanced by a meaningful equity base and cash holdings, suggesting a leverage ratio that is manageable for a recurring revenue business.

From an investor’s perspective, this margin and cash flow profile underscores why CooperCompanies stock is often considered a play on stable medical consumables rather than high volatility, binary outcome technologies. Gross margin in the mid sixties percent range and operating margin in the mid teens, combined with mid single to high single digit revenue growth, can create compounding over time if maintained. The company’s ability to invest in capacity, product development, and selective acquisitions without materially stressing its balance sheet is central to how the market assesses its long term earnings power.

CooperVision contact lens revenue exceeds $2 billion

CooperVision, CooperCompanies’ largest division, focuses on the global contact lens market. In fiscal 2025, divisional revenue reached roughly $2.1 billion as noted above, exceeding the $2.0 billion level achieved in fiscal 2024. This around five percent increase reflects continued penetration of silicone hydrogel lenses, including daily disposable products that cater to patient preferences for convenience and hygiene. Eye care practitioners frequently recommend these premium lenses, and CooperVision has targeted this trend with an expanded portfolio across both spherical and toric categories.

In addition to daily disposables, CooperVision’s revenue base includes monthly and two week replacement lenses. However, the divisional growth profile in the recent fiscal periods has been skewed toward products that carry higher average selling prices, such as advanced toric and multifocal lenses. By gradually shifting its portfolio mix toward these categories, CooperVision elevates gross margin, which contributes to CooperCompanies’ overall margin stability. This strategy is visible in the divisional gross margin metrics reported in the company’s filings, where CooperVision gross margin has been maintained or slightly improved in the mid sixties percent range despite input cost pressures in manufacturing.

CooperVision also benefits from geographic diversification. Revenue is spread across North America, Europe, Asia Pacific, and Latin America, with the United States still representing a significant share but with notable contributions from markets such as Japan, the United Kingdom, and continental Europe. This diversification helps balance currency effects and local economic cycles, smoothing overall divisional performance. For CooperCompanies stock, this means that investors are exposed to a broad global demand profile for contact lenses rather than a single region specific story.

Women’s health and fertility add a second growth pillar

CooperSurgical, CooperCompanies’ women’s health division, provides medical devices, fertility solutions, and prenatal diagnostics. In fiscal 2025, divisional revenue stood close to $1.0 billion, up from just under that level in fiscal 2024, according to the company’s annual disclosures. The growth here has been driven by demand for fertility related products and services, as well as certain devices used in obstetrics and gynecology. While margins in CooperSurgical can vary by product line, the division as a whole contributes meaningful earnings and provides diversification away from pure eye care.

In recent years, CooperSurgical has pursued a strategy of acquiring specialized businesses within fertility and women’s health, integrating their offerings into its broader portfolio. Acquisitions completed in prior fiscal periods have helped lift divisional revenue and broaden the company’s presence in clinics and hospitals. The revenue figures reported for fiscal 2025 reflect both organic growth and the full year consolidation of businesses acquired in earlier periods. This activity has implications for CooperCompanies stock because it signals that management is willing to deploy capital to strengthen the second pillar of its business while maintaining focus on integration and margin protection.

Reported operating income contributions from CooperSurgical in the latest annual period are in the low hundreds of millions of dollars, with divisional operating margin generally in the mid teens percent range. This margin profile, slightly lower than CooperVision but still robust, supports the overall company margin. For investors, the women’s health and fertility segment may be seen as a way to participate in structural demand trends, such as increased use of assisted reproductive technologies, while balancing exposure to the more mature but still growing contact lens market.

CooperVision daily disposable lens portfolio

One representative product line within CooperCompanies’ broader portfolio is CooperVision’s family of daily disposable contact lenses. These include a range of silicone hydrogel lenses designed for single day wear, covering spherical prescriptions, astigmatism via toric designs, and presbyopia via multifocal geometries. The company’s filings and product literature indicate that daily disposables have been a key driver of CooperVision’s revenue growth, particularly in developed markets where patients and practitioners prioritize convenience and hygiene.

The daily disposable category aligns well with CooperCompanies’ recurring revenue business model. Each lens is used once, implying that patients purchase substantial quantities over time. This creates a stream of repeat purchases and provides visibility for manufacturing and distribution planning. Moreover, the premium positioning of many daily disposable products supports CooperVision’s gross margin profile. For CooperCompanies stock, the importance of this product line lies in its ability to underpin both growth and profitability over multiple fiscal years, as adoption of daily disposables continues to rise globally.

CooperCompanies stock and market valuation context

CooperCompanies stock is listed on the New York Stock Exchange under the ticker symbol NYSE: COO. As of a recent trading day in mid 2026, the shares traded at a price in the low to mid hundreds of dollars per share, reflecting the market’s assessment of the company’s earnings trajectory and growth prospects. The company’s market capitalization, at that same time, stood in the multi billion dollar range, consistent with its status as a significant mid to large cap medical device issuer within the United States equity market.

Stock price performance over the prior twelve months has broadly tracked the company’s earnings delivery and sector sentiment. With fiscal 2025 revenue at about $3.1 billion versus $2.9 billion in fiscal 2024 and net income inching higher over the same period, investors have had reason to view the company as a steady compounder rather than a high growth, high volatility name. The share price in mid 2026 has been positioned within a band that reflects this profile, neither at a distressed level nor near speculative extremes. For those examining CooperCompanies stock, valuation metrics such as the price to earnings ratio and enterprise value to EBITDA multiple are often used to compare the company with peers in the ophthalmic device and women’s health spaces.

Analysts covering CooperCompanies typically frame their assessments around the sustainability of mid single to high single digit revenue growth, the stability of mid teens operating margin, and the company’s ability to deploy capital into acquisitions and capacity expansion while maintaining balance sheet discipline. While individual price targets and rating changes vary, the common thread in coverage is attention to whether CooperVision and CooperSurgical can continue to grow at or above market rates without eroding profitability. CooperCompanies’ track record in fiscal 2024 and fiscal 2025, with revenue rising from around $2.9 billion to approximately $3.1 billion and net income also progressing, provides a factual base for these discussions.